#Africa

Three curators discuss their recent exhibitions and the pivotal role of HIV and AIDS posters.

Health researchers are testing the flying bots in remote rural regions and congested urban areas alike.

A new global alliance launches to end AIDS in children by 2030. Currently, only half of children with HIV are on lifesaving treatment.

Generic cabotegravir, an every-other-month injectable to prevent HIV, will arrive in select countries. WHO and Health Gap have opinions.

The nation tops the list of countries that not only include trans people in their plans to end HIV but also back policy with funding.

As a Black leader, an HIV advocate and the father of a lesbian, Archbishop Desmond Tutu was one of us, writes AIDS United’s Jesse Milan.

A new study measures HIV and LGBTQ health equity and finds that HIV care providers are key health leaders. [VIDEO]

The federal HIV funding goes to 31 local housing programs and seven global data collection centers.

Abbott researchers found a high proportion of elite HIV controllers in the Democratic Republic of Congo, which could lead to cure insights.

This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.

UNAIDS hopes nations will follow the lead of a number of sub-Saharan African countries that are gaining control of their HIV epidemics.

The company also has plans to study monthly islatravir’s efficacy as HIV prevention among men who have sex with men.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

More studies link dolutegravir and other drugs to weight gain among people with HIV.

The REPRIEVE study, which is primarily looking at a statin’s effect on cardiovascular disease, is shedding light on many other mysteries.

Previously, kids weighing 44 to 88 pounds had to take lower doses—which are less available worldwide—and do so more than once a day.